Related Experiment Video
Updated: Mar 19, 2026

The Goeckerman Regimen for the Treatment of Moderate to Severe Psoriasis
Published on: July 11, 2013
Rexinoids for prevention and treatment of cancer: opportunities and challenges
Karen T Liby1, Michael B Sporn
1Michigan State University, Department of Pharmacology & Toxicology, B430 Life Science Building, 1355 Bogue Street, East Lansing, MI 48824. liby.kare@msu.edu.
Abstract:
Rexinoids are selective ligands for the nuclear receptors known as RXRs. They do not bind to the receptors for all-trans-retinoic acid (RARs). Many new rexinoids have been synthesized and then assayed for their ability to suppress proliferation of cancer cells, to inhibit activation of inflammatory cells of the tumor microenvironment, and to prevent carcinogenesis in animal models relevant to human disease. Here we review the literature on the effects of 4 such rexinoids: bexarotene, LG100268, LG101506, and NRX194204. These rexinoids also have potent synergistic effects when used in combination with other active pharmacological agents, and practical clinical applications would benefit from these actions.
Insights
Rexinoids selectively target nuclear receptors (RXRs) and show promise in cancer therapy. These compounds suppress cancer cell growth, reduce inflammation, and prevent cancer in animal models, offering synergistic therapeutic potential.
Area of Science:
- Pharmacology
- Oncology
- Molecular Biology
Background:
- Rexinoids are selective ligands for Retinoid X Receptors (RXRs), distinct from Retinoic Acid Receptors (RARs).
- Emerging research highlights rexinoids' potential in cancer treatment and prevention.
Purpose of the Study:
- To review the literature on four specific rexinoids: bexarotene, LG100268, LG101506, and NRX194204.
- To summarize their effects on cancer cell proliferation, inflammatory cell activation, and carcinogenesis.
Main Methods:
- Literature review of studies investigating rexinoid activity.
- Analysis of preclinical data from animal models of human disease.
Main Results:
- The reviewed rexinoids demonstrated efficacy in suppressing cancer cell proliferation.
- These agents inhibited the activation of inflammatory cells within the tumor microenvironment.
- Rexinoids showed potential in preventing carcinogenesis in relevant animal models.
Conclusions:
- The rexinoids studied possess significant anti-cancer and anti-inflammatory properties.
- They exhibit potent synergistic effects when combined with other pharmacological agents.
- These findings suggest promising clinical applications for rexinoids in cancer therapy.
More Related Videos
Related Concept Videos
The Retinoblastoma Gene
The first-ever tumor suppressor gene called Rb was identified in retinoblastoma - a rare eye tumor in children. In inherited forms of the disease, a child inherits one defective copy of the Rb gene, which predisposes them to retinoblastoma. However,...
The Retinoblastoma Gene
Cancer Prevention
Some...
Cancer Prevention
Acne Infection
Inhibition of Cdk Activity

